Abstract 1862P
Background
Cancer related fatigue (CRF) is a common side effect of cancer and cancer treatment that impacts every aspect of quality of life. To our knowledge, the statistics for prevalence in pediatrics are lacking in Egypt. The aim of this study is to record the prevalence of fatigue and its significant predicting factors in pediatric oncology patients.
Methods
We interviewed children aged 8-18 years with cancer, prescribed chemotherapy and not in severe distress. After the consent of the guardian is taken, the children personally filled 2 fatigue-related questionnaires (PROMIS Pediatric Short Forms of Fatigue (PROMIS fatigue), pedsQL multidimensional fatigue (PedsQL fatigue)) and 3 symptoms related questionnaires.
Results
42 children (47.6% female) (mean age 12.1 years (SD 3.3 years)) participated. Half of the children were in primary school (n=21, 50%) and most of them had their parents accompanying them (n=35, 83.3%). Most children suffered from a hematological tumor (n=35, 83.3%) and didn’t suffer from other chronic health conditions (n=39, 92.8%). Reported moderate to severe fatigue in children is between half to third of the children depending on the measurement tool used. The mean T-score for PROMIS fatigue was 53.76 (SD 12.5), the mean score for PedsQL fatigue was 74.27 (SD 21.79). Stepwise standardized multivariant linear regression showed that fatigue following PROMIS fatigue could be predicted by depressive symptoms.
Conclusions
CRF is multifactorial and prevalent among children and adolescents with cancer. Moreover, predicting factors differed between different tools as they measure fatigue from different dimensions. PedsQL fatigue was predicted by more factors. There is a need to include fatigue screening for pediatric oncology patients and incorporate its management in the medical care plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05